Literature DB >> 9299579

Androgen-regulated gene expression in prostate cancer.

J Trapman1, K B Cleutjens.   

Abstract

Androgen-regulated gene expression is mediated by the ligand-activated androgen receptor. Androgen receptor target genes contain in the regulatory regions one or more androgen response elements. Development of the male urogenital tract, including the prostate, depends on an activated androgen receptor. Similarly, growth of the majority of prostate cancers is androgen-dependent. Therefore, endocrine therapy, aimed at inhibition of androgen receptor functioning, has been applied for many years. However, during therapy, apparently androgen receptor independent cancers continue to grow. In general, these tumors still express the androgen receptor, suggesting a functional role of the androgen receptor. In a proportion of late stage prostate tumors, mutations and amplification of the androgen receptor gene have been found. Additionally, it has been hypothesized that ligand-independent androgen receptor activation can be involved in hormone refractory prostate cancer.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9299579     DOI: 10.1006/scbi.1997.0050

Source DB:  PubMed          Journal:  Semin Cancer Biol        ISSN: 1044-579X            Impact factor:   15.707


  19 in total

1.  The profile of prostate epithelial cytokines and its impact on sera prostate specific antigen levels.

Authors:  Yosra Bouraoui Mechergui; Awatef Ben Jemaa; Chekib Mezigh; Benito Fraile; Nawfel Ben Rais; Ricardo Paniagua; Mar Royuela; Ridha Oueslati
Journal:  Inflammation       Date:  2009-04-28       Impact factor: 4.092

2.  Antiandrogens Inhibit ABCB1 Efflux and ATPase Activity and Reverse Docetaxel Resistance in Advanced Prostate Cancer.

Authors:  Yezi Zhu; Chengfei Liu; Cameron Armstrong; Wei Lou; Amandeep Sandher; Allen C Gao
Journal:  Clin Cancer Res       Date:  2015-05-20       Impact factor: 12.531

Review 3.  Antiandrogens in prostate cancer.

Authors:  P Reid; P Kantoff; W Oh
Journal:  Invest New Drugs       Date:  1999       Impact factor: 3.850

4.  The smooth muscle gamma-actin gene is androgen responsive in prostate epithelia.

Authors:  R A Filmore; D A Dean; W E Zimmer
Journal:  Gene Expr       Date:  2002

5.  Androgen receptor CAG repeat length and association with prostate cancer risk: results from the prostate cancer prevention trial.

Authors:  Douglas K Price; Cindy H Chau; Cathee Till; Phyllis J Goodman; Caitlin E Baum; Sandy B Ockers; Bevin C English; Lori Minasian; Howard L Parnes; Ann W Hsing; Juergen K V Reichardt; Ashraful Hoque; Catherine M Tangen; Alan R Kristal; Ian M Thompson; William D Figg
Journal:  J Urol       Date:  2010-10-16       Impact factor: 7.450

Review 6.  Molecular mechanisms of castration-resistant prostate cancer progression.

Authors:  Smitha S Dutt; Allen C Gao
Journal:  Future Oncol       Date:  2009-11       Impact factor: 3.404

7.  Identification of a negative regulatory cis-element in the enhancer core region of the prostate-specific antigen promoter: implications for intersection of androgen receptor and nuclear factor-kappaB signalling in prostate cancer cells.

Authors:  Bekir Cinar; Fan Yeung; Hiroyuki Konaka; Marty W Mayo; Michael R Freeman; Haiyen E Zhau; Leland W K Chung
Journal:  Biochem J       Date:  2004-04-15       Impact factor: 3.857

8.  RhoGDIα downregulates androgen receptor signaling in prostate cancer cells.

Authors:  Yezi Zhu; Chengfei Liu; Ramakumar Tummala; Nagalakshmi Nadiminty; Wei Lou; Allen C Gao
Journal:  Prostate       Date:  2013-08-06       Impact factor: 4.104

9.  Accumulation of trans-1-amino-3-[(18)F]fluorocyclobutanecarboxylic acid in prostate cancer due to androgen-induced expression of amino acid transporters.

Authors:  Hiroyuki Okudaira; Shuntaro Oka; Masahiro Ono; Takeo Nakanishi; David M Schuster; Masato Kobayashi; Mark M Goodman; Ikumi Tamai; Keiichi Kawai; Yoshifumi Shirakami
Journal:  Mol Imaging Biol       Date:  2014-12       Impact factor: 3.488

10.  Androgen receptor CAG repeat length and TMPRSS2:ETS prostate cancer risk: results From the Prostate Cancer Prevention Trial.

Authors:  William D Figg; Cindy H Chau; Douglas K Price; Cathee Till; Phyllis J Goodman; Yonggon Cho; Marileila Varella-Garcia; Juergen K V Reichardt; Catherine M Tangen; Robin J Leach; Adrie van Bokhoven; Ian M Thompson; M Scott Lucia
Journal:  Urology       Date:  2014-05-10       Impact factor: 2.649

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.